Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real‐Word Cohort of Patients With Myeloproliferative Neoplasms
Despite treatment, AP remains prevalent, highlighting the need for targeted symptom management. <b>Trial registration</b>: ClinicalTrials.gov identifier: NCT02897297.
Authors
- Jean‐Christophe Ianotto (ORCID: https://orcid.org/0000-0001-9074-7287)
- Laetitia Rio
- Lanig Civi
- Wayne‐Corentin Lambert
- C. Le Gall‐Ianotto (ORCID: https://orcid.org/0000-0003-0158-2850)
- Brigitte Pan‐Petesch (ORCID: https://orcid.org/0000-0001-9853-2635)
- Éric Lippert (ORCID: https://orcid.org/0000-0002-2312-6584)
- Laura Herbreteau
- L. Misery (ORCID: https://orcid.org/0000-0001-8088-7059)
Institutions
- Inserm (FR)
- Université de Bretagne Occidentale (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Groupement d'Intérêt Economique (FR)
Publication Details
- Journal
- eJHaem
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/jha2.70197
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00